Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | -0.00 | 0.02 |
| FCF Yield | -5.83% | -15.65% | -19.60% | -20.39% |
| EV / EBITDA | -4.91 | 1.57 | 0.87 | -4.65 |
| Quality | ||||
| ROIC | -16.79% | -8.87% | -15.52% | -18.76% |
| Gross Margin | -63.76% | 61.18% | 54.18% | 44.90% |
| Cash Conversion Ratio | 0.90 | 0.52 | 0.99 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 37.19% | 2,142,129.02% | 2,157,275.07% | 2,161,064.21% |
| Free Cash Flow Growth | 7.39% | -13.34% | 22.21% | -89.64% |
| Safety | ||||
| Net Debt / EBITDA | 4.41 | 8.17 | 4.33 | 1.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.55 | 0.12 | 0.14 | 0.20 |
| Cash Conversion Cycle | 305.17 | 555.17 | 569.32 | 359.26 |